ISOLPHARM 中铜放射性同位素生产的早期评估。

Early Evaluation of Copper Radioisotope Production at ISOLPHARM.

机构信息

Legnaro National Laboratories, National Institute of Nuclear Physics, 35020 Legnaro, Italy.

Department of Physics and Earth Science, University of Ferrara, 44122 Ferrara, Italy.

出版信息

Molecules. 2018 Sep 24;23(10):2437. doi: 10.3390/molecules23102437.

DOI:10.3390/molecules23102437

PMID:30249975

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6222311/

Abstract

The ISOLPHARM (ISOL technique for radioPHARMaceuticals) project is dedicated to the development of high purity radiopharmaceuticals exploiting the radionuclides producible with the future Selective Production of Exotic Species (SPES) Isotope Separation On-Line (ISOL) facility at the Legnaro National Laboratories of the Italian National Institute for Nuclear Physics (INFN-LNL). At SPES, a proton beam (up to 70 MeV) extracted from a cyclotron will directly impinge a primary target, where the produced isotopes are released thanks to the high working temperatures (2000 °C), ionized, extracted and accelerated, and finally, after mass separation, only the desired nuclei are collected on a secondary target, free from isotopic contaminants that decrease their specific activity. A case study for such project is the evaluation of the feasibility of the ISOL production of Cu and Cu using a zirconium germanide target, currently under development. The producible activities of Cu and Cu were calculated by means of the Monte Carlo code FLUKA, whereas dedicated off-line tests with stable beams were performed at LNL to evaluate the capability to ionize and recover isotopically pure copper.

摘要

ISOLPHARM（用于放射性药物的 ISOL 技术）项目致力于开发高纯度放射性药物，利用未来在意大利国家核物理研究所莱尼亚诺国家实验室的选择性生产 exotic species（SPES）同位素在线分离（ISOL）设施可生产的放射性核素。在 SPES 中，从回旋加速器提取的质子束（高达 70 MeV）将直接撞击主靶，在主靶中，由于工作温度高（2000°C），产生的同位素被释放，被离化、提取和加速，最后，经过质量分离，只有所需的核被收集在次级靶上，没有降低其比活度的同位素杂质。该项目的一个案例研究是评估使用目前正在开发的锆锗化物靶进行 ISOL 生产 Cu 和 Cu 的可行性。通过蒙特卡罗代码 FLUKA 计算了 Cu 和 Cu 的可生产活度，而在 LNL 进行了专用的离线稳定束测试，以评估离化和回收同位素纯铜的能力。